Luke Nathaniel Walker insider trades

Open-market stock purchases and sales by Luke Nathaniel Walker, Director at Context Therapeutics Inc, from SEC Form 4 filings since Sep 18, 2017.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +110%.

Recent trades

DateStockTradeValue
Jun 24, 2026CNTX Context Therapeutics IncBought (not open market)—
Jun 16, 2026ZNTL Zentalis Pharmaceuticals, IncBought (not open market)—

Companies traded

  • CNTX Context Therapeutics Inc: other filings, last Jun 24, 2026
  • ZNTL Zentalis Pharmaceuticals, Inc: 1 buy, last Jun 16, 2026
  • HARP Harpoon Therapeutics, Inc: other filings, last Mar 11, 2024
  • CASC Cascadian Therapeutics, Inc: other filings, last Mar 9, 2018

Get free alerts when Luke Nathaniel Walker files a new trade →